RxDoctor Payments Data

Bert Blackwell, DO

Undersea and Hyperbaric Medicine · Tulsa, OKNPI 1649221177

Payments from drug & device makers

$974in general payments, 2019–2025

Across 36 payments — averaging $27.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Integra Lifesciences Corporation$543
  • Novo Nordisk$154
  • Smith+Nephew$61
  • Organogenesis Inc.$61
  • Johnson & Johnson$34
  • Dexcom, Inc.$24
  • plus $95 from 5 others

What the payments were for

  • Food & beverage$974100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

Too few undersea and hyperbaric medicine providers in Oklahomato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$58,466
Medicare patients
149
Services billed
897

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide673$636,388
JardianceEmpagliflozin813$484,222
EliquisApixaban259$149,678
Spiriva RespimatTiotropium Bromide165$85,826
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog108$62,376
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog151$52,457
Tresiba Flextouch U-100Insulin Degludec198$38,652
XifaxanRifaximin12$37,860
InvokanaCanagliflozin58$33,659
AlogliptinAlogliptin Benzoate184$31,913
EntrestoSacubitril/Valsartan44$30,484
Fluticasone-SalmeterolFluticasone Propion/Salmeterol212$24,231
Novolog FlexpenInsulin Aspart243$22,319
Combivent RespimatIpratropium/Albuterol Sulfate44$20,762
SynthroidLevothyroxine Sodium475$17,131

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$154$636,388673 claims
PfizerEliquis$20$149,678259 claims
Johnson & JohnsonInvokana$34$33,65958 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few undersea and hyperbaric medicine providers in Oklahomaon file to place this against a meaningful peer group, so we don't.

Other undersea and hyperbaric medicine in Tulsa

Where these figures come from

Is this you, or does something look wrong? →